anti-TNFR2 monoclonal antibody SIM1811-03

A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against tumor necrosis factor receptor 2 (TNFR2; tumor necrosis factor receptor superfamily member 1B; TNFRSF1B), with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities Upon administration, anti-TNFR2 monoclonal antibody SIM1811-03 targets and binds to TNFR2 expressed on immune suppressive cells, such as tumor-associated regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME). This induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and depletes these TNFR2-expressing immune suppressive cells. Also, SIM1811-03 prevents the activation of TNFR2 by endogenous tumor necrosis factor (TNF) and TNFR2-mediated signaling, blocks the activation of the nuclear factor kappa B (NF-kB) signaling pathway, halts TNFR2-mediated immunosuppression, thereby inhibiting the proliferation and function of Tregs and enhancing cytotoxic T-cell-mediated anti-tumor immune responses. In addition, SIM0235 is able to bind to TNFR2 expressed on the surface of tumor cells, thereby killing TNFR2-expressing tumor cells directly. TNFR2, a member of the TNFR family of co-stimulatory molecules, plays a role in tumor necrosis factor signaling, tumor expansion and survival. It is primarily expressed on the surface of tumor cells and suppressive immune cells in the TME, but rarely in normal human tissues or peripheral immune cells.